Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | DTYMK | P23919 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23802590 | 0.84 | GPR119 (0.50) | GPR119RORCPOLBNR1H2NAMPT | |
| SCHEMBL23802575 | 0.80 | GPR119 (0.49) | GPR119RORCPOLBNR1H2NAMPT | |
| SCHEMBL23802591 | 0.80 | GPR119 (0.49) | GPR119RORCPOLBNR1H2NAMPT | |
| SCHEMBL2992043 | 0.74 | GPR119 (0.53) | GPR119RORCPOLBNR1H2NAMPT | |
| SCHEMBL2996726 | 0.73 | GPR119 (0.50) | GPR119POLBNR1H2NAMPTDTYMK | |
| SCHEMBL23802302 | 0.72 | GPR119 (0.46) | GPR119POLBNR1H2NAMPTDTYMK | |
| SCHEMBL2995903 | 0.71 | GPR119 (0.51) | GPR119POLBNR1H2NAMPTUSP30 | |
| SCHEMBL23802301 | 0.71 | GPR119 (0.51) | GPR119RORCPOLBNR1H2NAMPT | |
| SCHEMBL23802337 | 0.71 | GPR119 (0.48) | GPR119POLBNR1H2NAMPTDTYMK | |
| SCHEMBL572706 | 0.70 | NR1H2 (0.53) | GPR119RORCNR1H2NAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276977-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | ALKERMES, INC. | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276977-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC11 | GPR119 1656/4885RORC 599/4885POLB 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.